US OptionsDetailed Quotes
OLLI250117C82500
- 21.00
- 0.000.00%
15min DelayClose Jan 10 16:00 ET
0.00High0.00Low
21.00Open21.00Pre Close0 Volume5 Open Interest82.50Strike Price0.00Turnover92.53%IV-2.69%PremiumJan 17, 2025Expiry Date23.86Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9838Delta0.0031Gamma4.43Leverage Ratio-0.0451Theta0.0142Rho4.36Eff Leverage0.0057Vega
Ollie's Bargain Outlet Stock Discussion
Sign in to post a comment
Jim Cramer highlighted several budget-friendly retail stocks that are thriving as consumers seek better prices amid inflation. ![]()
Cramer noted that while consumers aren't necessarily cash-strapped, they are fed up with high prices and are seeking bargains. He pointed to $Walmart (WMT.US)$ and $Costco (COST.US)$ , with their low-cost offerings, as particularly appealing. Walmart and Costco have risen 30% year to date, whereas $Walgreens Boots Alliance (WBA.US)$ and ...
Cramer noted that while consumers aren't necessarily cash-strapped, they are fed up with high prices and are seeking bargains. He pointed to $Walmart (WMT.US)$ and $Costco (COST.US)$ , with their low-cost offerings, as particularly appealing. Walmart and Costco have risen 30% year to date, whereas $Walgreens Boots Alliance (WBA.US)$ and ...
From YouTube
6
2
Ollie's had a mediocre quarter despite outperforming EPS and Same Store Sales estimates, as revenue missed and full-year guidance fell short. The company's stock fell 4.1% and future performance may be influenced by its valuation, business qualities, and recent results.
2
The market seems less excited about Ollie's Bargain Outlet Holdings than before, which could present an investment opportunity. The recent improvement in returns could suggest a positive shift within the business.
1
CEO notes strong closeout deal flow as consumers look to save on branded items, creating more opportunities. FY24 revenue estimated at $2.097B to $2.104B with an EPS of $2.77 to $2.83, outpacing consensus estimate.
1
CEO John Swygert expresses positive sentiments on Ms. Baglivo's appointment, stating that they're seeking to benefit from her extensive marketing and advertising experience and overall business acumen for executing their growth strategies and building the Ollie's brand.
Despite market incorporating OLLI's future growth, the stock appears steep due to high P/E ratio. Potential investors might find the current price prohibitive, while shareholders may consider selling, assuming stock should trade below current price due to high industry P/E ratio.
Q2 results impacted individual stocks with Ollie's, Nordstrom, Five Below, Dillard's, and Macy's witnessing a drop. Ollie’s improved outlook could lift its share price, while Nordstrom and Dillard's showed resilience. Macy's and Five Below's performance fell short, causing investor worry due to Macy's weaker annual guidance.
Gapping up
$HP Inc (HPQ.US)$ +2.6% (JPMorgan upgraded computer builder to overweight from neutral, saying it expects the PC industry to see upward revisions for the second half of this year. JPMorgan also downgraded Dell to neutral from overweight, citing its preference for HP's expected recovery, as Dell's PC segment will likely be offset by other factors. )
$Prometheus Biosciences (RXDX.US)$ +69% (The company will be acquired by $Merck & Co (MRK.US)$ for $10.8...
$HP Inc (HPQ.US)$ +2.6% (JPMorgan upgraded computer builder to overweight from neutral, saying it expects the PC industry to see upward revisions for the second half of this year. JPMorgan also downgraded Dell to neutral from overweight, citing its preference for HP's expected recovery, as Dell's PC segment will likely be offset by other factors. )
$Prometheus Biosciences (RXDX.US)$ +69% (The company will be acquired by $Merck & Co (MRK.US)$ for $10.8...
13
Upgrades
• $AutoZone (AZO.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $2,296 (from $1,969)
• $Chewy (CHWY.US)$ : Needham Upgrades to Buy from Hold - PT $55
• $National Vision (EYE.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $32 (from $31)
• $Fresenius Medical Care (FMS.US)$ : Jefferies Upgrades to Buy from Underperform - PT $33.70 (from $30.30)
• $Gitlab (GTLB.US)$ : Goldman Sachs Upgrades to Buy from Neutral - ...
• $AutoZone (AZO.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $2,296 (from $1,969)
• $Chewy (CHWY.US)$ : Needham Upgrades to Buy from Hold - PT $55
• $National Vision (EYE.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $32 (from $31)
• $Fresenius Medical Care (FMS.US)$ : Jefferies Upgrades to Buy from Underperform - PT $33.70 (from $30.30)
• $Gitlab (GTLB.US)$ : Goldman Sachs Upgrades to Buy from Neutral - ...
22
4
Gainers:
• $Signet Jewelers (SIG.US)$ +7.6% (In reaction to earnings/guidance)
• $Oxford Industries (OXM.US)$ +6.3% (In reaction to earnings/guidance)
• $BridgeBio Pharma (BBIO.US)$ +5%(to Present Phase 2b Data and Pivotal Phase 3 Study Design of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) at the Endocrine Society (ENDO) 2022 Annual Conference)
• $Greif (GEF.US)$ +4.6% (In reaction to earnings/guidance)
• $Olema Pharmaceuticals (OLMA.US)$ +4.3% (an...
• $Signet Jewelers (SIG.US)$ +7.6% (In reaction to earnings/guidance)
• $Oxford Industries (OXM.US)$ +6.3% (In reaction to earnings/guidance)
• $BridgeBio Pharma (BBIO.US)$ +5%(to Present Phase 2b Data and Pivotal Phase 3 Study Design of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) at the Endocrine Society (ENDO) 2022 Annual Conference)
• $Greif (GEF.US)$ +4.6% (In reaction to earnings/guidance)
• $Olema Pharmaceuticals (OLMA.US)$ +4.3% (an...
21
3
No comment yet
Sonnytrades : If Cramer likes the stock... you know what happens next
MikejonesDaTrader Sonnytrades :
